Biological prognostic factors for early stage completely resected non-small cell lung cancer

Cagini, Lucio; Monacelli, Massimo; Giustozzi, Giammario; Moggi, L; Bellezza, Guido; Sidoni, Angelo; Bucciarelli, E; Darwish, Samir; Ludovini, Vienna; Pistola, Lorenza; Gregorc, Vanesa; Tonato, Maurizio

doi:10.1002/1096-9098(200005)74:1<53::aid-jso13>3.0.co;2-d

Cited by 47 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemistry used to reveal Ki-67 protein was not always performed with the same antibody: clone Mib-1 in the majority of the studies (Costes et al, 1995;Bohm et al, 1996;Fontanini et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Minami et al, 2002;Rigau et al, 2002), antibodies coming from a firm selling several clones but without mention of the clone used (Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Giaccone et al, 1995;Pujol et al, 1996;Mehdi et al, 1998;Soomro et al, 1998;Carbognani et al, 2002); any mention of the antibodies used (Tungekar et al, 1991;Harpole Jr et al, 1995Giatromanolaki et al, 1996a, b;D'Amico et al, 1999D'Amico et al, , 2000Carvalho et al, 2000;Pelosi et al, 2001)…”

Section: Discussionmentioning

confidence: 99%

“…In total, 42 studies published between 1991 and 2002 were selected for this systematic review (Tungekar et al, 1991;Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Costes et al, 1995;Giaccone et al, 1995;Harpole, Jr et al, 1995Bohm et al, 1996;Fontanini et al, 1996;Giatromanolaki et al, 1996a, b;Pujol et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Mehdi et al, 1998;Soomro et al, 1998;D'Amico et al, 1999D'Amico et al, , 2000Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Carvalho et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Pelosi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Carbognani et al, 2002;Minami et al, 2002;Rigau et al, 2002). Five were excluded because an identical patients cohort was used in another selected publication (references excluded/includ...…”

Section: Studies Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49% of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As there was no statistical difference in quality scores between the significant and nonsignificant studies evaluable for the meta-analysis, we were allowed to aggregate the survival results. The combined hazard ratio for NSCLC, calculated using a random-effects model was 1.56 (95% CI: 1.30 -1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Studies Characteristicsmentioning

confidence: 99%

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The association between Bcl-2 expression and prognosis in NSCLC is still unclear: some studies show improved outcome [13,[28][29][30][31][32][33][34] and others no survival advantage [35][36][37]. An association between Bcl-2 and poor prognosis should be expected because Bcl-2 inhibits apoptosis and should therefore favor cell proliferation.…”

Section: Discussionmentioning

confidence: 99%

The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer

Gregorc¹,

Darwish²,

Ludovini³

et al. 2003

Lung Cancer

View full text Add to dashboard Cite

“…This is highlighted by the experience with p53. Of six studies that have evaluated four or more markers (including p53) simultaneously, three studies found an independent effect of p53 (6,30,51), whereas the remaining three did not (24,31,52). Second, most of these studies are limited by the large number of hypotheses tested in one group of patients, without confirmation of their findings in any validation cohorts.…”

Section: Reviewmentioning

confidence: 99%

Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review

Singhal¹,

Vachani

Antin‐Ozerkis

et al. 2005

Clinical Cancer Research

267

231

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death in the U.S. with survival restricted to a subset of those patients able to undergo surgical resection. However, even with surgery, recurrence rates range from 30% to 60%, depending on the pathologic stage. With the advent of partially effective, but potentially toxic adjuvant chemotherapy, it has become increasingly important to discover biomarkers that will identify those patients who have the highest likelihood of recurrence and who thus might benefit most from adjuvant chemotherapy. Hundreds of papers have appeared over the past several decades proposing a variety of molecular markers or proteins that may have prognostic significance in non^small cell lung cancer. This review analyzes the largest and most rigorous of these studies with the aim of compiling the most important prognostic markers in early stage non^small cell lung cancer. In this review, we focused on biomarkers primarily involved in one of three major pathways: cell cycle regulation, apoptosis, and angiogenesis. Although no single marker has yet been shown to be perfect in predicting patient outcome, a profile based on the best of these markers may prove useful in directing patient therapy. The markers with the strongest evidence as independent predictors of patient outcome include cyclin E, cyclin B1, p21, p27, p16, survivin, collagen XVIII, and vascular endothelial cell growth factor.

show abstract

Biological prognostic factors for early stage completely resected non-small cell lung cancer

Cited by 47 publications

References 35 publications

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer

Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review

Contact Info

Product

Resources

About